These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
498 related articles for article (PubMed ID: 24738666)
1. Using a drug-safety tool to prevent competition. Sarpatwari A; Avorn J; Kesselheim AS N Engl J Med; 2014 Apr; 370(16):1476-8. PubMed ID: 24738666 [No Abstract] [Full Text] [Related]
2. The ongoing regulation of generic drugs. Frank RG N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956 [No Abstract] [Full Text] [Related]
3. Branded drug reformulation: the next brand vs. generic antitrust battleground. Amoresano GV Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032 [No Abstract] [Full Text] [Related]
4. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma. Wang Z Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001 [No Abstract] [Full Text] [Related]
5. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers. Soehnge H Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584 [No Abstract] [Full Text] [Related]
6. Generics battle brand names over mortality of drug patents. Betz R J Healthc Resour Manag; 1995 Jul; 13(7):35-7. PubMed ID: 10144008 [No Abstract] [Full Text] [Related]
7. Settlements between brand and generic pharmaceutical companies: a reasonable antitrust analysis of reverse payments. Yvon AM Fordham Law Rev; 2006 Dec; 75(3):1883-912. PubMed ID: 17312596 [No Abstract] [Full Text] [Related]
8. Countering delays in introduction of generic drugs. Lancet; 2002 Jan; 359(9302):181. PubMed ID: 11812545 [No Abstract] [Full Text] [Related]
10. Strategies that delay or prevent the timely availability of affordable generic drugs in the United States. Jones GH; Carrier MA; Silver RT; Kantarjian H Blood; 2016 Mar; 127(11):1398-402. PubMed ID: 26817958 [TBL] [Abstract][Full Text] [Related]
11. Delaying generic competition--corporate payoffs and the future of Plavix. Shuchman M N Engl J Med; 2006 Sep; 355(13):1297-300. PubMed ID: 17005945 [No Abstract] [Full Text] [Related]
12. A Citizen's Pathway Gone Astray - Delaying Competition from Generic Drugs. Feldman R; Wang C N Engl J Med; 2017 Apr; 376(16):1499-1501. PubMed ID: 28248550 [No Abstract] [Full Text] [Related]
13. Congress works to permit 'biosimilar' drugs very soon. Carroll J Manag Care; 2009 Apr; 18(4):7-8. PubMed ID: 19472559 [No Abstract] [Full Text] [Related]
14. Variations in time of market exclusivity among top-selling prescription drugs in the United States. Wang B; Liu J; Kesselheim AS JAMA Intern Med; 2015 Apr; 175(4):635-7. PubMed ID: 25664700 [No Abstract] [Full Text] [Related]
16. A precarious balancing act--the role of the FDA as protector of public health and industry wealth. McCabe AR Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844 [No Abstract] [Full Text] [Related]
17. Realizing two-tiered innovation policy through drug regulation. Ridgway WE Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807 [No Abstract] [Full Text] [Related]
19. Drug marketing exclusivity under United States and European Union law. Junod V Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347 [No Abstract] [Full Text] [Related]